ric allogeneic hct for high-risk mds
Published 3 years ago • 106 plays • Length 1:26Download video MP4
Download video MP3
Similar videos
-
1:02
update on treatments for high- and low-risk mds
-
4:39
aml & mds: mac or ric?
-
1:17
the curative potential of allosct in the treatment of hr-mds
-
5:57
ric transplant in cr1 for older aml patients
-
1:32
next-generation sequencing for low-risk mds
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
2:22
haplo-sct for older patients with aml/hr-mds: should age be a barrier to transplantation?
-
26:08
crrt fluid balance and composition - m. ostermann
-
9:03
iccs education: minimal/measurable residual disease testing (mrd) by flow cytometry in bll
-
34:34
monthly rate calculator (mrc) recorded webinar
-
1:32
stem cell transplantation conditioning in aml: making the decision between mac and ric
-
2:14
addressing the high rate of disease relapse following allosct in patients with aml
-
4:58
clinical outcomes of cryopreserved graft recipients following allo-hct
-
1:57
combining molecular and clinical data to predict survival & transformation risk in patients with mds
-
0:52
is there a role for combination therapy in cml?
-
1:16
ric vs mac in mrd-positive & mrd-negative patients with aml
-
4:00
immunotherapies for the treatment of high-risk mm
-
6:50
ifcc clinical case 4:transient abnormal myelopoiesis down syndrome with thrombocytosis in 24 days ol
-
1:44
imerge update: continuous transfusion independence & disease modification with imetelstat in lr-mds
-
1:34
australasian lymphoma alliance consensus practice statement on the diagnosis and management of fl
-
3:32
a polygenic risk score to determine a patient's predisposition to cll
-
1:25
the recent approval of imetelstat in lr-mds based on results of the imerge trial